The study demonstrates BBB crossing but doesn't elucidate the transport mechanisms involved. This knowledge gap limits optimization of delivery efficiency and understanding of EV biodistribution in the CNS. Gap type: unexplained_observation Source paper: Engineered MSC-EVs loaded with BDNF-enhancing neuropeptides via a non-disruptive method enhance post-stroke neuroregeneration via intranasal delivery. (None, None, PMID:40883738)
Landscape Summary: What mechanisms enable neuropeptide-loaded MSC-EVs to cross the blood-brain barrier via intranasal delivery? is a 0.78 priority gap in neurotherapeutics. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
What mechanisms enable neuropeptide-loaded MSC-EVs to cross the blood-brain barrier via intranasal delivery? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No knowledge graph edges recorded
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: